Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX – Get Free Report) have received an average recommendation of “Moderate Buy” from the sixteen ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $156.6923.
Several brokerages recently issued reports on ABVX. The Goldman Sachs Group started coverage on shares of Abivax in a research note on Wednesday, September 9th. They set a “buy” rating and a $155.00 price objective on the stock. Citigroup reaffirmed an “outperform” rating on shares of Abivax in a research note on Tuesday, June 2nd. Citizens Jmp restated a “market outperform” rating and set a $187.00 price objective on shares of Abivax in a report on Wednesday, July 1st. Wedbush cut their target price on Abivax from $140.00 to $118.00 and set a “neutral” rating on the stock in a research report on Tuesday. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $180.00 target price on shares of Abivax in a report on Friday, July 24th.
View Our Latest Stock Report on Abivax
Hedge Funds Weigh In On Abivax
Abivax Trading Down 4.2%
NASDAQ:ABVX opened at $94.13 on Monday. The firm has a market cap of $8.22 billion, a price-to-earnings ratio of -15.53 and a beta of 0.96. The company’s 50-day moving average is $119.17 and its two-hundred day moving average is $117.41. Abivax has a 12-month low of $69.81 and a 12-month high of $148.83.
Abivax (NASDAQ:ABVX – Get Free Report) last released its quarterly earnings results on Monday, September 21st. The company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.68). The business had revenue of $1.37 million for the quarter, compared to the consensus estimate of $0.80 million. On average, equities research analysts forecast that Abivax will post -3.22 earnings per share for the current fiscal year.
Key Headlines Impacting Abivax
Here are the key news stories impacting Abivax this week:
- Positive Sentiment: Barclays maintained an Overweight rating and set a $148 price target, signaling confidence in Abivax’s long-term opportunity and implying meaningful potential upside. Tickerreport analyst coverage
- Positive Sentiment: Truist retained its Buy rating while lowering its target to $151 from $155. Although the reduction reflects a more cautious valuation, the continued Buy recommendation suggests the firm expects important value creation from Abivax’s pipeline. Benzinga analyst coverage
- Positive Sentiment: Investors are focused on two potentially decisive catalysts for obefazimod, including progress toward regulatory approval for ulcerative colitis and additional clinical developments. Positive outcomes could materially improve the investment case. Abivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts
- Neutral Sentiment: Analyst coverage remains divided: Wedbush cut its target to $118 from $140 and moved to Neutral, while other firms continue to publish bullish targets. This divergence highlights the stock’s dependence on clinical execution. Analysts Offer Insights on Healthcare Companies
- Negative Sentiment: Abivax reported a wider first-half net loss and missed quarterly EPS expectations by $0.79, despite revenue exceeding estimates. The company remains loss-making, increasing investor sensitivity to cash usage and future financing needs. Abivax H1 Net Loss Widens
- Negative Sentiment: The company plans to submit an obefazimod New Drug Application for ulcerative colitis by the end of 2026, but the timeline leaves substantial regulatory and clinical execution risk before commercialization. Abivax Releases Earnings Results
Abivax Company Profile
Abivax is a clinical-stage biotechnology company headquartered in Paris, France, focused on developing oral therapies for chronic inflammatory and immune-mediated diseases. Its lead investigational product is obefazimod, an oral small-molecule therapy designed to enhance the production of microRNA-124, a regulator of inflammatory pathways.
Obefazimod is being developed primarily for ulcerative colitis, a chronic inflammatory disease of the colon, and has also been evaluated in Crohn’s disease.
Featured Stories
- Five stocks we like better than Abivax
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
